MRO Magazine

Interrad Medical Awarded Federal Supply Schedule Contract for Its SecurAcath Catheter Securement Device


September 21, 2015
By Business Wire News

PLYMOUTH, Minn.

Interrad Medical announces it has been awarded the Federal Supply Schedule (FSS) contract for its SecurAcath catheter securement device.

“We welcome this opportunity to add VA and DoD hospitals to the growing list of institutions using the SecurAcath to maintain vascular access for the entire duration of therapy,” said Joe Goldberger, President and CEO of Interrad Medical. He added, “The timing of this award is excellent because it coincides with the launch of the improved ergonomic SecurAcath design.”

The SecurAcath offers the potential of a dramatically lower catheter dislodgement rate based on clinical studies. Lower dislodgement rates mean replacing fewer catheters which can significantly decrease catheter replacement costs and total cost of patient care. The SecurAcath increases efficiency by decreasing the time required to secure, maintain and remove catheters. The SecurAcath lasts the life of the catheter and does not need to be replaced weekly. Its design allows for improved catheter site cleaning and minimizes catheter movement which may reduce catheter-related infections. Finally, the SecurAcath is sutureless, therefore, eliminating the potential for costly needle stick injuries that can occur when suturing catheters.

About Interrad Medical, Inc.
Plymouth, Minnesota-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices designed for minimally-invasive interventional and surgical procedures. The Company was founded by practicing Interventional Radiologist and Interrad Medical Chairman and Chief Medical Officer, Michael Rosenberg, M.D. For more information or to order, visit www.securacath.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.

Interrad Medical, Inc.
Jeff Killion, 763-225-6699
Chief Marketing Officer
jeff@interradmedical.com